New and Emerging Therapies for the Treatment of Non-alcoholic Steatohepatitis: The Role of the Pharmacist in Early Identification and Clinical Intervention
1.5 Credits / Nephrology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Caring for Patients With Chronic Graft-versus-Host Disease: The Important Role of Pharmacists on the Cancer Care Team
1.5 Credits / Hematology, Oncology
View More
Assessing the Role of Antibody-Drug Conjugates in Breast Cancer Treatment Pathways
1.0 Credit / Oncology
View More
Opportunities to Optimize Treatment of Non-Small Cell Lung Cancer and Gastric Cancers With Antibody-Drug Conjugates
1.0 Credit / Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Disease, Respiratory, Immunization
View More
Continuing the Conversation: A Review of Targeted Therapies for Early-Stage Breast Cancer
0.5 Credit / Oncology, Women’s Health
View More
Demystifying the Details of T-Cell Engaging Bispecific Antibodies: Establishing a Foundation for Oncology Pharmacists
2.0 Credits / Oncology
View More
FDA Grants Fast Track Designation to Milvexian for Multiple Prospective Cardiovascular Indications
June 6th 2023The proposed indications for milvexian include stroke prevention after an acute ischemic stroke or high-risk transient ischemic attack; recent acute coronary syndrome; and atrial fibrillation.
Obstructive Sleep Apnea May Have Significant Impact on Cognitive Decline in Middle-Aged Individuals
Recent debates have surrounded whether cognitive deficits, specifically in middle-aged patients, may be driven by cardiovascular and metabolic comorbidities instead of distinct obstructive sleep apnea processes.
Overall Survival Results Reinforce Osimertinib is Now Standard of Care for EGFRm Stage IB–IIIA NSCLC
June 5th 2023Updated overall survival and safety profile data from the global phase 3 ADAURA trial provide practice-changing findings with adjuvant osimertinib (Tagrisso; AstraZeneca) in patients with resected EGFR-mutated stage IB–IIIA NSCLC.